In order to strengthen its antibody-drug conjugate (ADC) pipeline, Bristol Myers Squibb (BMS) has entered into an agreement with German biotech, Tubulis, to develop next-generation ADCs for the treatment of solid tumours. BMS had agreed to pay US$22.75 M upfront and committed up to US$1 B in milestone payments to gain access to Tubulis’ Tubutecan payloads in combination with its proprietary P5 conjugation platform. The deal marks yet another move by BMS to secure a place in the growing ADC market.